Scopolamine, also known as hyoscine, or devil's breath, is a natural or synthetically produced tropane alkaloid and anticholinergic drug that is formally used as a medication for treating motion sickness and postoperative nausea and vomiting. It has applications in prevention of nausea, vomiting, and dizziness associated with motion sickness and recovery from anesthesia and surgery. Scopolamine may also be used to treat certain stomach or intestinal problems, such as spastic muscle states, diverticulitis, irritable bowel syndrome, Parkinson-like conditions etc.
The global scopolamine API market is estimated to be valued at US$ 292.96 million in 2022 and is expected to exhibit a CAGR of 5.3% during the forecast period (2022-2030).
Figure 1.Global Scopolamine API Market Share (%), by Form, 2022
Increasing number of surgeries globally is expected to drive growth of the scopolamine API market
Scopolamine is used as a medication for treating postoperative nausea and vomiting. Thus the rising number of surgeries is expected to drive the market growth over the forecast period. For instance, according to the news provided by the Asiri Central’s Brain and Spine Centre, in March 2020, Colombo marked a significant milestone recently of having performed 10,000 neurosurgical procedures since it was established in June 2010. The hospital has treated an average of 1,000 patients per year over the past five years
Figure 2.Global Scopolamine API Market Share (%), by Purity, 2022
Increasing product launch by key players in the market is expected to drive the market growth during the forecast period.
The key players in the market are adopting organic growth strategies such as product launch, which is expected to drive the market growth over the forecast period. For instance, in October 2019, Perrigo Company plc, an over-the-counter consumer goods and specialty pharmaceutical company, announced the relaunch of the AB rated generic equivalent of Transderm Scop (scopolamine 1.5 mg), used to treat the symptoms of nausea or vomiting.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2021 | Market Size in 2022: | US$ 292.96 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 |
| Forecast Period 2022 to 2030 CAGR: | 5.3% | 2030 Value Projection: | US$ 442.72 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Phytex Australia., Aspen Holdings, LGM Pharma, Midas Pharma GmbH, Transo-Pharm Handels-GmbH, Aktin Chemicals,Inc, Merck KgaA, Alchem International Pvt. Ltd., Tiefenbacher API + Ingredients GmbH & Co. KG, Spectrum Chemical, Vital Laboratories Pvt Ltd, Clearsynth, Prism Industries Ltd, Alkaloids Corporation., and Manus Aktteva Biopharma LLP |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Global Scopolamine API Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
COVID-19 can affect the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of products from one place to another
The COVID-19 pandemic had a negative effect on the global scopolamine API market due to the decline in surgical operations for chronic conditions brought on by the ongoing COVID-19 pandemic. According to an article published by the Wolters Kluwer Health,Inc. an organization providing professional information, software solutions, and services for the health, tax & accounting, governance, risk & compliance, and legal & regulatory sectors, the COVID-19 pandemic has led to significant disruption in the provision of surgical services, with an estimated cancellation of 28 million operations worldwide during the first wave of covid alone.
Global Scopolamine API Market: Restraint
The major factor that hinder growth of the global scopolamine API market include side effects associated with scopolamine and misuse of scopolamine. Scopolamine may cause side effects such as dry mouth, sleepiness, urinary retention, agitation, dilated pupils, sore throat, drowsiness, dizziness, etc. Some side effects can be serious which include rash, redness, difficulty speaking, seizure, painful or difficulty urinating, stomach pain, nausea, vomiting, etc.
Key Players
Major players operating in the global scopolamine API market include Phytex Australia., Aspen Holdings, LGM Pharma, Midas Pharma GmbH, Transo-Pharm Handels-GmbH, Aktin Chemicals,Inc, Merck KgaA, Alchem International Pvt. Ltd., Tiefenbacher API + Ingredients GmbH & Co. KG, Spectrum Chemical, Vital Laboratories Pvt Ltd, Clearsynth, Prism Industries Ltd, Alkaloids Corporation., and Manus Aktteva Biopharma LLP
Scopolamine is an alkaloid drug extracted from a plant called henbane to treat nausea and motion sickness and further to dilate the pupil in ophthalmic procedures. Scopolamine belongs to a class of drugs called anticholinergic. Scopolamine is a tropane alkaloid isolated from members of the Solanaceae family of plants, similar to atropine and hyoscyamine, all of which structurally mimic the natural neurotransmitter acetylcholine. It works by blocking the activity of the neurotransmitter acetylcholine, which stimulates the part of the brain that triggers nausea and vomiting, involuntary muscle movement in the lungs, and the gastrointestinal and urinary tracts. Scopolamine is also used in medicine as a sedative or hypnotic and sometimes with morphine to relieve pain. Scopolamine has also been prescribed ‘off label’ for depression, asthma, as a smoking-cessation remedy, and to relieve the nausea that accompanies chemotherapy
Market Dynamics
Scopolamine is effective in reducing depression and anxiety symptoms due to its anxiety-reducing (anxiolytic) effects. Thus the increasing number of people suffering from anxiety is expected to drive the market growth over the forecast period. For instance, according to the Anxiety and Depression Association of America, anxiety disorders are the most common mental illness in the U.S. affecting about 40 million adults aged 18 years and older, or 18.1% of the population every year in the U.S.
Moreover, increasing adoption of drug delivery systems such as transdermal patches is expected to drive the market growth over the forecast period. The scopolamine transdermal skin patch is used to prevent nausea and vomiting caused by motion sickness or recovery from anesthesia and surgery.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients